Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study

Tyler W. Buckner, MD MSc, Michelle Witkop, DNP, FNP-BC, Christine Guelcher, PPCNP, Robert F. Sidonio, Jr., MD, Christopher E. Walsh, MD PhD, Craig M. Kessler, MD, David Clark, PhD, Wendy E. Owens, MA, Neil Frick, MS, Neeraj N Iyer, PhD, David L Cooper, MD MBA

Blood (2016) 128 (22): 251.

https://doi.org/10.1182/blood.V128.22.251.251

Published: 2016

Journal Articles

Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

Katharine Batt, MD MSc, Michael Recht, MD PhD, Michael Wang, MD, Doris V. Quon, MD PhD, Lisa N Boggio, MD MS, Craig M. Kessler, MD, Tyler W. Buckner, MD MSc, Anne T. Neff, MD, Neeraj N Iyer, PhD, David L Cooper, MD MBA, Christine L Kempton, MD MSc

Blood (2016) 128 (22): 252.

https://doi.org/10.1182/blood.V128.22.252.252

Published: 2016

Journal Articles

Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries

Guy Young, MD, Miguel Escobar, Steven Pipe, MD, David L. Cooper, MD MBA

Blood (2015) 126 (23): 2302.

https://doi.org/10.1182/blood.V126.23.2302.2302

Published: 2015

Journal Articles

Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

Christine L Kempton, MD MSc, Michael Recht, MD PhD, Anne Neff, MD, Michael Wang, MD, Tyler W. Buckner, MD MSc, Amit Soni, MD, Doris Quon, MD PhD, Michelle Witkop, DNP, FNP-BC, Lisa Boggio, MD, David L Cooper, MD MBA

Blood (2015) 126 (23): 39.

https://doi.org/10.1182/blood.V126.23.39.39

Published: 2015

Journal Articles

Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database

Michael Wang, MD, Anissa Cyhaniuk, MS, David L Cooper, MD MBA, Neeraj N Iyer, PhD

Blood (2015) 126 (23): 3271.

https://doi.org/10.1182/blood.V126.23.3271.3271

Published: 2015

Journal Articles

Unmet Needs in Diagnosis and Treatment of Glanzmann’s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses

Meera B. Chitlur, MD, Michael Recht, MD PhD, Madhvi Rajpurkar, MD, Ellis J. Neufeld, MD PhD, Craig M. Kessler, MD, Mark Reding, Michael Tarantino, MD, David L. Cooper, MD MBA

Blood (2014) 124 (21): 2179.

https://doi.org/10.1182/blood.V124.21.2179.2179

Published: 2014

Journal Articles

Impact of Glanzmann’s Thrombasthenia (GT): Perceptions from US Patients and Parents

Michael Recht, MD PhD, Madhvi Rajpurkar, MD, Meera B. Chitlur, MD, Mark Reding, Mary Jane Frey, RN, BSN, CPN, Skye Peltier, MPH, PA-C, Christine Guelcher, MS, PNP-BC, Dana Stephens, RN, MS, CPNP, David L. Cooper, MD MBA

Blood (2014) 124 (21): 4853.

https://doi.org/10.1182/blood.V124.21.4853.4853

Published: 2014

Journal Articles

Is Bleeding In Hemophilia Really Spontaneous Or Activity Related: Analysis Of US Patient/Caregiver Data From The Hemophilia Experiences, Results and Opportunities (HERO) Study

Leonard A. Valentino, MD, FAAP, Angela Forsyth, Michelle Witkop, DNP, FNP-BC, Christine Guelcher, Angela Lambing, David L. Cooper, MD, MBA

Blood (2013) 122 (21): 2364.

https://doi.org/10.1182/blood.V122.21.2364.2364

Published: 2013

Journal Articles

Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data

Anissa Cyaniuk, MS, David L. Cooper, MD, MBA, Desiree Hall, MS, David Ungar, MD, Chioma Smith, MPH, Tami Wisniewski, MPH

Blood (2013) 122 (21): 2947.

https://doi.org/10.1182/blood.V122.21.2947.2947

Published: 2013

Journal Articles

Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study

Alice D. Ma, MD, Craig M. Kessler, MD, Hamid A B Al-Mondhiry, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 4624.

https://doi.org/10.1182/blood.V120.21.4624.4624

Published: 2012

Journal Articles

The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US

Craig M. Kessler, MD, Alice D. Ma, MD, Hamid A B Al-Mondhiry, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 4625.

https://doi.org/10.1182/blood.V120.21.4625.4625

Published: 2012

Journal Articles

A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project

Steven R. Lentz, MD, PhD, Anand Tandra, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 3371.

https://doi.org/10.1182/blood.V120.21.3371.3371

Published: 2012

Journal Articles

US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry

Hamid A B Al-Mondhiry, MD, Alice D. Ma, MD, Craig M. Kessler, MD, Margaret Fisher, PharmD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 3372.

https://doi.org/10.1182/blood.V120.21.3372.3372

Published: 2012

Journal Articles

Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life

Diane J Nugent, MD, Chris Guelcher, MD, PNP-BC, Angela Forsyth, PT, DPT, Neil Frick, MS, Michelle Rice, Alfonso Iorio, MD, PhD, Tami Wisniewski, MPH, David L. Cooper, MD, MBA

Blood (2012) 120 (21): 4244.

https://doi.org/10.1182/blood.V120.21.4244.4244

Published: 2012

Journal Articles

Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,

Alice D. Ma, MD, Craig M. Kessler, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3374.

https://doi.org/10.1182/blood.V118.21.3374.3374

Published: 2011

Journal Articles

Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry,

Ellis J. Neufeld, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3314.

https://doi.org/10.1182/blood.V118.21.3314.3314

Published: 2011

Journal Articles

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Amy D. Shapiro, MD, Ellis J. Neufeld, MD, PhD, Victor S. Blanchette, MD, FRCPC, Hervé Chambost, MD, PhD, Peter Salaj, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3316.

https://doi.org/10.1182/blood.V118.21.3316.3316

Published: 2011

Journal Articles

Barriers to the Effective Diagnosis and Management of a Bleeding Patient with Undiagnosed Bleeding Disorder Across Multiple Specialties: Results of a Quantitative Case-Based Survey.

Mark T. Reding, MD, David L. Cooper, MD, MBA

Blood (2010) 116 (21): 3673.

https://doi.org/10.1182/blood.V116.21.3673.3673

Published: 2010

Journal Articles

The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven ® RT) In Acquired Hemophilia.

Steven R. Lentz, MD, PhD, Anand Tandra, MD, Tracy J. Peters, David L. Cooper, MD, MBA

Blood (2010) 116 (21): 3674.

https://doi.org/10.1182/blood.V116.21.3674.3674

Published: 2010

Journal Articles

Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX.

Amy D. Shapiro, MD, Ellis J. Neufeld, MD, PhD, David L. Cooper, MD, MBA

Blood (2010) 116 (21): 3675.

https://doi.org/10.1182/blood.V116.21.3675.3675

Published: 2010

NARROW

Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study

Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries

Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study

Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database

Unmet Needs in Diagnosis and Treatment of Glanzmann’s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses

Impact of Glanzmann’s Thrombasthenia (GT): Perceptions from US Patients and Parents

Is Bleeding In Hemophilia Really Spontaneous Or Activity Related: Analysis Of US Patient/Caregiver Data From The Hemophilia Experiences, Results and Opportunities (HERO) Study

Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data

Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study

The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US

A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project

US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry

Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life

Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,

Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry,

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Barriers to the Effective Diagnosis and Management of a Bleeding Patient with Undiagnosed Bleeding Disorder Across Multiple Specialties: Results of a Quantitative Case-Based Survey.

The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven ® RT) In Acquired Hemophilia.

Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only